Targeting IL-23 in psoriasis: current perspectives

Christina Fotiadou, Elizabeth Lazaridou, Eleni Sotiriou, Demetrios Ioannides First Department of Dermatology and Venereology, Aristotle University Medical School, Thessaloniki, Greece Abstract: The recent advances in the understanding of psoriasis pathogenesis have clarifi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Psoriasis IL-23 Treatment Th17 Axis anti-IL23P19 monoclonal antibodies Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/c6d38008c9c84fdcac40012401ac9465
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6d38008c9c84fdcac40012401ac9465
record_format	dspace
spelling	oai:doaj.org-article:c6d38008c9c84fdcac40012401ac94652021-12-02T00:42:35ZTargeting IL-23 in psoriasis: current perspectives2230-326Xhttps://doaj.org/article/c6d38008c9c84fdcac40012401ac94652018-01-01T00:00:00Zhttps://www.dovepress.com/targeting-il-23-in-psoriasis-current-perspectives-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XChristina Fotiadou, Elizabeth Lazaridou, Eleni Sotiriou, Demetrios Ioannides First Department of Dermatology and Venereology, Aristotle University Medical School, Thessaloniki, Greece Abstract: The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important than IL-12 in the pathogenesis of psoriasis. Based on that background, the selective targeting of the IL-23p19 subunit emerged as an attractive therapeutic option and led to the development of a new category of biologic agents. Three monoclonal antibodies that selectively inhibit the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, are in the pipeline for the treatment of moderate-to-severe psoriasis. In this article, we review the most recent efficacy and safety data regarding these IL-23p19 inhibitors. Keywords: psoriasis, IL-23, treatment, Th17 axis, anti-IL-23p19 monoclonal antibodiesFotiadou CLazaridou ESotiriou EIoannides DDove Medical PressarticlePsoriasisIL-23TreatmentTh17 Axisanti-IL23P19 monoclonal antibodiesDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 8, Pp 1-5 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psoriasis IL-23 Treatment Th17 Axis anti-IL23P19 monoclonal antibodies Dermatology RL1-803
spellingShingle	Psoriasis IL-23 Treatment Th17 Axis anti-IL23P19 monoclonal antibodies Dermatology RL1-803 Fotiadou C Lazaridou E Sotiriou E Ioannides D Targeting IL-23 in psoriasis: current perspectives
description	Christina Fotiadou, Elizabeth Lazaridou, Eleni Sotiriou, Demetrios Ioannides First Department of Dermatology and Venereology, Aristotle University Medical School, Thessaloniki, Greece Abstract: The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important than IL-12 in the pathogenesis of psoriasis. Based on that background, the selective targeting of the IL-23p19 subunit emerged as an attractive therapeutic option and led to the development of a new category of biologic agents. Three monoclonal antibodies that selectively inhibit the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, are in the pipeline for the treatment of moderate-to-severe psoriasis. In this article, we review the most recent efficacy and safety data regarding these IL-23p19 inhibitors. Keywords: psoriasis, IL-23, treatment, Th17 axis, anti-IL-23p19 monoclonal antibodies
format	article
author	Fotiadou C Lazaridou E Sotiriou E Ioannides D
author_facet	Fotiadou C Lazaridou E Sotiriou E Ioannides D
author_sort	Fotiadou C
title	Targeting IL-23 in psoriasis: current perspectives
title_short	Targeting IL-23 in psoriasis: current perspectives
title_full	Targeting IL-23 in psoriasis: current perspectives
title_fullStr	Targeting IL-23 in psoriasis: current perspectives
title_full_unstemmed	Targeting IL-23 in psoriasis: current perspectives
title_sort	targeting il-23 in psoriasis: current perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/c6d38008c9c84fdcac40012401ac9465
work_keys_str_mv	AT fotiadouc targetingil23inpsoriasiscurrentperspectives AT lazaridoue targetingil23inpsoriasiscurrentperspectives AT sotirioue targetingil23inpsoriasiscurrentperspectives AT ioannidesd targetingil23inpsoriasiscurrentperspectives
_version_	1718403523685646336

Targeting IL-23 in psoriasis: current perspectives

Ejemplares similares